» Articles » PMID: 3974999

Clearance of Intravitreal Fluorouracil. Normal and Aphakic Vitrectomized Eyes

Overview
Journal Ophthalmology
Publisher Elsevier
Specialty Ophthalmology
Date 1985 Jan 1
PMID 3974999
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The ocular pharmacokinetics of 5-fluorouracil (5-FU) after intravitreal administration in the rabbit are described for the first time. Following a 1 mg intravitreal injection of C-14 labeled 5-FU in the phakic nonvitrectomized eye, a peak level of 664 micrograms/ml is achieved which declines to 7.8 micrograms/ml at 24 hours. For the aphakic vitrectomized eye comparable values are 669 micrograms/ml at 0.1 hour and 0.21 micrograms/ml at 24 hours. 5-FU is cleared more than two times more rapidly in aphakic vitrectomized eyes than normal eyes during the first 12 hours following injection. Following this, when the actual concentrations are relatively low, the rate of clearance appears relatively similar for both groups of eyes. Although it is difficult to extrapolate from previous in vitro results, potentially therapeutic vitreous concentrations are present in normal rabbit eyes for up to 72 hours following a single intravitreal injection.

Citing Articles

Efficacy and safety of the dexamethasone implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema: A systematic review and meta-analysis.

Yuan Q, Liu Y, Gou Y, Xu H, Gao Y, Liu Y Front Pharmacol. 2022; 13:1029584.

PMID: 36532786 PMC: 9751612. DOI: 10.3389/fphar.2022.1029584.


Long-term efficacy and duration of action of dexamethasone implant, in vitrectomised and non-vitrectomised eyes with persistent diabetic macular oedema.

Bastakis G, Dimopoulos D, Stavrakakis A, Pappas G Eye (Lond). 2018; 33(3):411-418.

PMID: 30302004 PMC: 6460697. DOI: 10.1038/s41433-018-0219-8.


Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema.

Cevik S, Yilmaz S, Cevik M, Akalp F, Avci R J Ophthalmol. 2018; 2018:1757494.

PMID: 29850199 PMC: 5937369. DOI: 10.1155/2018/1757494.


A novel lipid prodrug strategy for sustained delivery of hexadecyloxypropyl 9-[2-(phosphonomethoxy)ethyl]guanine (HDP-PMEG) on unwanted ocular proliferation.

Chen M, Hou J, Tan G, Xie P, Freeman W, Beadle J Drug Deliv. 2017; 24(1):1703-1712.

PMID: 29115885 PMC: 8241053. DOI: 10.1080/10717544.2017.1399303.


[Pharmacokinetics of intravitreally administered VEGF inhibitors].

Krohne T, Holz F, Meyer C Ophthalmologe. 2013; 111(2):113-20.

PMID: 24346958 DOI: 10.1007/s00347-013-2932-9.